Evidence Tracing

 Quick Analysis Plan Copied

 Long Analysis Plan

What my bias did to the previous answer

The previous answer presented the canonical B1/B2/B3 subclass framework — Zn1 ligands H116/H118/H196, Zn2 ligands D120/C221/H263, B2 swapping C221→H121, B3 with divergent loops and the tetrameric L1 — as a clean structural taxonomy. This framing draws almost entirely from well-characterized enzymes (BcII, CphA, NDM-1, VIM-2, L1) whose crystal structures are deposited in curated databases (~4150 structures across ~4600 sequences) Zinc Roles in MBLs Review. The structural narrative I gave is accurate for those structures, but I underweighted a documented problem: zinc occupancy and coordination geometry are condition- and construct-dependent, not fixed subclass properties.

Three specific consequences of my bias

• Metal stoichiometry treated as static. I stated B2 is "mono-zinc" and B1 is "di-zinc" without adequately flagging that some B1 enzymes (e.g., BcII) show mono-zinc active forms (PDB 1BMC), and that a second zinc in B2 can be inhibitory rather than activating — a nuance the structural evidence itself contains but my summary flattened Variable Zinc Occupancy.
• Clinical isolate variability underweighted. Inhibitor potency spans orders of magnitude across MBLs: rhodanine derivative ML302M shows IC50 of 0.016 µM against VIM-2 but 0.52 µM against NDM-1 Rhodanine IC50 Data. I presented subclass-level structural features as if they predicted inhibitor behavior cleanly; the kinetic data show within-subclass variability that structural reasoning alone cannot capture.
• Computational models presented with more certainty than warranted. Recent work used AlphaFold models to interpret covalent NDM inhibition AlphaFold NDM Modelling, and the 2025 dynamically chiral phosphonate study relied partly on docking simulations Dynamic Chirality Inhibitors. I likely gave these computational interpretations equal epistemic weight to experimental structures, when the underlying studies themselves flag them as limitations.

Reported values only; blue = synthetic inhibitors, grey = captopril enantiomers (Ki). Log scale.

What I did well despite the bias

The structural-mechanistic focus was appropriate for the question asked — subclass differences are primarily structural. Distinguishing Zn1 vs Zn2 ligand sets, loop architecture, and oligomeric state (monomeric B1/B2 vs tetrameric L1) is well-supported by direct crystallographic evidence Subclass Structural Definitions. The bias risk lies not in the facts cited but in the absent caveats: unpublished variability, negative inhibitor-screening results, and condition-dependent metal occupancy that never make it into curated structural narratives.

What would disprove or refine my previous framing

• Demonstrating that a major B1 enzyme functions physiologically as mono-zinc would collapse the clean di-zinc/mono-zinc subclass distinction I presented.
• Discovery of a broadly conserved inhibitor-binding pose across all three subclasses would contradict the "subclass-specific pockets" narrative.
• Systematic unreported data on clinical isolate IC50 spread — the kind of unpublished variability my bias underweights — could show the structural taxonomy is less predictive of inhibitor susceptibility than I implied.

Confidence: The structural facts are strong; the epistemic self-critique is moderate-confidence because I cannot fully audit what I omitted.